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The inflammatory microenvironment induces tumours to acquire an aggressive and immunosuppressive behaviour. Since acid
sphingomyelinase (A-SMase) downregulation in melanoma was shown to determine a malignant phenotype, we aimed here to
elucidate the role of A-SMase in the regulation of tumour immunogenic microenvironment using in vivo melanoma models in
which A-SMase was either downregulated or maintained at constitutively high levels. We found high levels of inflammatory factors
in low A-SMase expressing tumours, which also displayed an immunosuppressive/protumoural microenvironment: high levels of
myeloid-derived suppressor cells (MDSCs) and regulatory T lymphocytes (Tregs), as well as low levels of dendritic cells (DCs).
In contrast, the restoration of A-SMase in melanoma cells not only reduced tumour growth and immunosuppression, but also
induced a high recruitment at tumour site of effector immune cells with an antitumoural function. Indeed, we observed a poor
homing of MDSCs and Tregs and the increased recruitment of CD8+ and CD4+ T lymphocytes as well as the infiltration of DCs
and CD8+/CD44high T lymphocytes.This study demonstrates that change of A-SMase expression in cancer cells is sufficient per se to
tune in vivomelanoma growth and that A-SMase levels modulate immune cells at tumour site.Thismay be taken into consideration
in the setting of therapeutic strategies.
1. Introduction
Malignant melanoma is a highly metastatic skin cancer char-
acterized by rapid growth, early metastasis, and resistance
to chemotherapy and radiotherapy [1]. In the past the
high immunogenic capacity of melanoma has fostered the
development of immunotherapeutic strategies based on the
stimulation of adaptive immunity T cell mediated against
specific tumour antigen [2]. However, despite initial promis-
ing studies, the overall outcomes of the clinical trials based
on immunotherapy are still far from being satisfying [3].
The lack of an effective immune reactivity to tumours may
be explained by the protracted inflammation that occurs
in melanoma microenvironment, eventually resulting in
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immunosuppression and thus in the failure of immune cells
to reject the tumour [4, 5]. The inflammatory microenviron-
ment in the tumour mass is the result of the secretion of
inflammatory cytokines by both melanoma and stromal cells
[6, 7]. It induces cancer cells to acquire a more aggressive
phenotype and allows the recruitment in the tumour lesion of
different immunosuppressive cells, such as myeloid-derived
suppressor cells (MDSCs) and, consequently, regulatory T
lymphocytes (Tregs) [5]. Various strategies have been used to
decrease MDSC amounts and immunosuppressive functions
in tumours, including melanomas [4, 8, 9]. However, the
molecular mechanisms leading to the control of intratu-
moural MDSCs are poorly understood. The elucidation
of these aspects may be crucial for the development of
new approaches in melanoma treatment aimed at reducing
MDSC-mediated immunosuppression.
In the last decades, the proapoptotic second messen-
ger ceramide has drawn the attention as a fundamental
player in cancer biology [10, 11]. Ceramide levels are signif-
icantly decreased in several tumours including melanomas,
colon cancers, ovarian cancers, and gliomas; interestingly
an inverse relationship has been found between ceramide
levels and the stratification of tumours with high- and low-
grade gliomas containing low and high levels of ceramide,
respectively [12–14]. Of interest it seems particularly clear
that cancer cells have evolved complexmechanisms to reduce
ceramide levels, possibly through the modulation of their
generating enzymes [15–17]. An example of this event is
the spontaneous downregulation of the ceramide-generating
enzyme acid sphingomyelinase (A-SMase) in melanoma cells
during tumour progression that accounts for a more aggres-
sive behaviour of melanomas in terms of tumour growth and
metastatic ability [18].
This work has been designed to elucidate the possible
role of A-SMase in determining melanoma immunogenic
capacity with a specific attention on the modulation of
tumour microenvironment. To this end, we analysed the
immune cell infiltration in a mouse model of melanoma
syngeneic transplant that is particularly aggressive and,
more importantly, that recapitulates the downregulation
of A-SMase during tumour progression [18]. A clone in
which A-SMase is maintained at constitutively high levels
during melanoma progression was analysed as well. We
found that the progressive loss of A-SMase enhanced the
immunosuppressive capacity of melanoma cells through the
recruitment of MDSCs and Tregs at tumour site and the
impairment of dendritic cells (DCs) maturation. Of impor-
tance, the upregulation of A-SMase enhanced the function of
immune effector cells as DCs and cytotoxic T lymphocytes.
This A-SMase-dependent modulation of microenvironment
events may have a therapeutic outcome in terms of tumour
growth.
2. Methods
2.1. Cell Models and Animals. The cell clones used in our
experiments were generated from the murine melanoma
cell line B16-F1 of American Type Culture Collection (LGC
Standards, Sesto San Giovanni, Italy). As described in
Bizzozero et al. [18], the low expressing A-SMase B16-
W6 pSIL10 clone was generated from a subclone of the
parental cell line B16-F1 (i.e., B16-W6) by transfecting the
cells with the plasmid pSilencer4.1-CMV (Invitrogen-Life
Technologies, Monza, Italy) harbouring a shRNA containing
a sequence which gave the A-SMase silencing. The control
clone used in our experiments (B16-pSILscr) was generated
by transfecting B16-W6 cells with the plasmid pSilencer4.1-
CMVharbouring a shRNA containing a scrambled sequence.
The B16-B1A clone overexpressing A-SMase was generated
as follows: the pEF1/Myc plasmid (Invitrogen-Life Tech-
nologies) containing cDNA for A-SMase [18] was trans-
fected in B16-F1 cells using the Fugene transfection reagent
(Promega, Milano, Italy), according to the manufacturer’s
protocol. Approximately 15 colonies resistant to the antibi-
otic G418 (500𝜇g/mL) were tested for A-SMase expression
and activity (see Section 3.3). A B16-F1 clone transfected
with the empty vector pEF1/Myc (B16-pEF1) was used as
control. Cells were routinely tested for Mycoplasma using a
BioWhittaker MycoAlert Mycoplasma Detection Kit (Lonza
Group, Basel, Switzerland). Cells were cultured in Iscove’s
modified Dulbecco’s medium supplemented with 10% heat-
inactivated foetal bovine serum (FBS), glutamine (200mM),
and penicillin/streptomycin (100U/mL) and grown at 37∘C
in a humidified atmosphere containing 5% CO
2
.
Female C57BL/6 mice (6–8 weeks old) were purchased
from Charles River Laboratories (Calco, Italy), housed in a
regulated environment (23 ± 1∘C, 50 ± 5% humidity) with a
12 h light/dark cycle (lights on at 08.00 a.m.), and provided
with food and water ad libitum. All studies were conducted
in accordance with the Italian law on animal care N∘
116/1992 and the European Communities Council Directive
EEC/609/86. The experimental protocols were approved by
the Ethics Committee of the University of Milan. All efforts
were made to reduce both animal suffering and the number
of animals used.
2.2. Animal Handling and Tumour Growth. Mice received
s.c. injections of 5 × 104 cells in the lower-right flank on
day 0 (ten animals per group at minimum) [18, 19]. Tumour
growth was monitored every 2-3 days by means of external
calliper measurements and volume calculation (length ×
width2/2), until mice reached IACUC euthanasia criteria,
as, for instance, clinical signs of tumour or when tumour
size exceeded 10% of body weight [19]. For PCR and flow
cytometry analysis tumours were resected when they reached
the volume of ca. 500mm3. Late stage melanomas were
explanted at a volume of ca. 1500mm3.
2.3. Quantitative Real Time-PCR (qPCR). The analysis of
mRNA expression was performed as previously described
[18, 20–22]. Briefly, total RNA from resected tumours and in
vitroB16 cloneswas extractedwith theHigh Pure RNATissue
Kit and the High Pure RNA Isolation Kit, respectively (Roche
Applied Science, Mannheim, Germany), according to the
manufacturer’s protocol. First-strand cDNA was generated
from 1 𝜇g of total RNA using iScript Reverse Transcription
Supermix (Bio-Rad, Hercules, CA, USA). As shown in
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Table 1: Primer pairs designed for PCR analysis.
Name Symbol Accession number Primer sequence Amplicon
IL-1𝛽 il1b NM 008361 F: 5
󸀠-GCAACTGTTCCTGAACTCAACT-3󸀠
R: 5󸀠-ATCTTTTGGGGTCCGTCAACT-3󸀠 89 bp
IL-6 il6 NM 031168 F: 5
󸀠-TAGTCCTTCCTACCCCAATTTCC-3󸀠
R: 5󸀠-TTGGTCCTTAGCCACTCCTTC-3󸀠 76 bp
Il-10 il10 NM 010548 F: 5
󸀠-GCTCTTACTGACTGGCATGAG-3󸀠
R: 5󸀠-CGCAGCTCTAGGAGCATGTG-3󸀠 105 bp
GM-CSF csf2 NM 009969 F: 5
󸀠-GGCCTTGGAAGCATGTAGAGG-3󸀠
R: 5󸀠-GGAGAACTCGTTAGAGACGACTT-3󸀠 104 bp
TGF-𝛽1 tgfb1 NM 011577 F: 5
󸀠-AAACGGAAGCGCATCGAA-3󸀠
R: 5󸀠-GGGACTGGCGAGCCTTAGTT-3󸀠 63 bp
TNF-𝛼 tnf NM 013693 F: 5
󸀠-TTCTGTCTACTGAACTTCGGGGTGATCGGTCC-3󸀠
R: 5󸀠-GTATGAGATAGCAAATCGGCTGACGGTGTGGG-3󸀠 354 bp
GAPDH gapdh NM 008084 F: 5
󸀠-ACCCAGAAGACTGTGGATGG-3󸀠
R: 5󸀠-ACACATTGGGGGTAGGAACA-3󸀠 172 bp
A-SMase(v.1,2) smpd1 NM 000543;NM 001007593
F: 5󸀠-TGGCTCTATGAAGCGATGGC-3󸀠
R: 5󸀠-TTGAGAGAGATGAGGCGGAGAC-3󸀠 125 bp
F: forward; R: reverse.
Table 1, a set of primer pairs amplifying fragments ranging
from63 to 354 bpwas designed to hybridise to unique regions
of the appropriate gene sequence. qPCRwas performed using
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad).
The fold change was determined relative to the control after
normalising to GAPDH (internal standard) through the use
of the formula 2−ΔΔCT.
2.4. Flow Cytometry. After surgical excision, a single cell
suspension from tumours was obtained by collagenase IV
(0.2mg/mL), dispase (2mg/mL), and DNase I (0.1mg/mL)
treatment in Iscove’s modified Dulbecco’s medium, sup-
plemented with 5% FBS, glutamine (200mM), and peni-
cillin/streptomycin (100U/mL). After 30 min at 37∘C in a
shaking bath, the cell suspension was filtered (40𝜇m pore-
size membrane) and washed in phosphate buffer saline (PBS)
added with 1% bovine serum albumin (BSA). Unspecific
sites were blocked incubating samples for 20min at room
temperature in PBS containing 10% goat serum and 1% BSA.
Cells were then incubated with fluorophore-conjugated anti-
bodies for the staining of specific cellular markers (Table 2)
in 1% BSA-PBS solution (1 h on ice). Cells were analysed by
flow cytometry using a Gallios Flow Cytometer (Beckman-
Coulter, Brea, CA, USA) and the software FCS Express 4 (De
Novo System, Portland, OR, USA).
2.5.Western Blotting. Theanalysis of protein expression from
in vitro B16 clones was performed as previously described
[18, 20–23].The rabbit polyclonal antimyc-tag (Cell Signaling
Technology, Danvers, MA, USA) and the mouse monoclonal
anti-TATA binding protein (TBP) (Abcam, Cambridge, UK)
primary antibodies were used in combinationwith the appro-
priate secondary antibodies HRP-conjugated (Bio-Rad). Pro-
teins were visualised using Bio-Rad Clarity Western ECL
substrate with a Bio-Rad ChemiDoc MP imaging system.
Bands were quantified for densitometry using the Bio-Rad
Image Lab software.
Table 2: List of the antibodies used in flow cytometry for immune
cells analysis.
Protein name Conjugation Clone
CD11b APC M1/70.15.11.5
Gr1 FITC RB6-8C5
CD4 PE-Cy5 GK1.5
CD8 PE-Cy5 eBioH35-17.2
CD44 PE-Cy7 IM7
CD25 PE-Cy7 PC61.5
Foxp3 PE 150D/E4
CD11c PE N418
CD80 FITC 16-10A1
MHCII PE-Cy5 M5/114.15.2
2.6. A-SMase Activity. Cells (2 × 106 cells/mL) were homo-
genised in the acid lysis buffer (50mM sodium acetate,
1% Triton X-100, and 1mM EDTA, pH 5) with freshly
added protease inhibitor cocktail (cOmplete, Roche Applied
Science) [24]. Sphingomyelinase activity was measured using
the Amplex Red Sphingomyelinase Assay Kit (Molecular
Probes-Life Technologies, Monza, Italy), as described in the
manufacturer’s protocol.
2.7. Apoptosis Detection. Apoptosis was measured by flow
cytometry as described previously [18]. Briefly, adherent
cells were detached using Enzyme-Free Cell Dissociation
Buffer (Merck Millipore Billerica, MA, USA), washed twice
with cold PBS, and incubated (1 × 106 cells) with 5𝜇L of
FITC-labelled annexin V (Life Technologies, Monza, Italy)
to detect phosphatidylserine exposure on the outer leaflet
of the plasma membrane and 5 𝜇L of propidium iodide (PI)
(eBioscience, San Diego, CA, USA) to exclude necrotic cells,
in binding buffer (10mMHEPES, 140 mMNaCl, and 2.5mM
CaCl
2
). After 15min of incubation at room temperature, cells
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were acquired using a Gallios Flow Cytometer (Beckman-
Coulter, Brea, CA, USA) and analysed by the software FCS
Express 4 (De Novo System, Portland, OR, USA).
2.8. Statistical Analysis. Upon verification of normal distri-
bution, statistical significance of raw data between the groups
in each experiment was evaluated using unpaired Student’s
𝑡-test (single comparisons) or one-way ANOVA followed by
the Newman-Keuls posttest (multiple comparisons). Data
belonging from different experiments were represented and
averaged in the same graph. Tumour growth was analysed
using two-way ANOVA, followed by the Bonferroni posttest.
The GraphPad Prism software package (Graph Software, San
Diego, CA, USA) was used. Results are expressed as means ±
standard error of the mean (SEM) of the indicated 𝑛 values.
2.9. Materials. Iscove’s modified Dulbecco’s medium, FBS,
glutamine, penicillin/streptomycin, HEPES, G418, and PBS
were purchased from Euroclone (Pero, Italy). Primer pairs
were obtained from Primm Biotech (Milano, Italy). Dispase
and DNase I were obtained from Gibco-Life Technologies
(Monza, Italy) and Roche Applied Science, respectively. Goat
serumwas purchased fromVector Laboratories (Burlingame,
CA, USA). Flow cytometry antibodies were purchased as
follows: CD11b and Gr1 fromMiltenyi Biotec, Bergisch Glad-
bach, Germany; CD11c, CD80, MHCII, CD4, CD8, CD25,
CD44, and Foxp3 from eBioscience, San Diego, CA, USA.
All other reagents were purchased from Sigma-Aldrich (Saint
Louis, MO, USA).
3. Results
3.1. Downregulation of A-SMase Increases the Accumulation
of MDSCs in Melanoma. We have previously demonstrated
that during B16-F1 melanoma progression A-SMase is spon-
taneously downregulated thus conferring to melanoma cells
a more aggressive phenotype [18]. To evaluate the impact of
this event on the modulation of tumour microenvironment,
micewere subcutaneously injectedwith B16-W6 pSIL10 cells,
a loss-of-function model of A-SMase obtained by the knock-
down of A-SMase in the parental cell line B16-F1 [18]; we
then analysed the in vivo behaviour of the established skin
melanoma in terms of cytokine expression and tumour-
infiltrating immune cells. The parental cell line B16-pSILscr
served as control.
ThemRNAanalysis by qPCR in the explantedmelanomas
of a panel of different inflammatory factors showed a
significant accumulation at B16-W6 pSIL10 tumour site of
interleukin- (IL-) 1𝛽, IL-6, IL-10, granulocyte-macrophage
colony-stimulating factor (GM-CSF), transforming growth
factor- (TGF-) 𝛽1, and tumour necrosis factor- (TNF-) 𝛼
(Figure 1(a)). A sustained secretion and maintenance of
inflammatory mediators during tumour progression stimu-
late the enrichment and activation of MDSCs then leading
to immunosuppression [4]. Thus, we evaluated the presence
of MDSCs (CD11b+/Gr1+ cells) in the tumour mass by flow
cytometry. As shown in Figure 1(b), we found a significant
increase in CD11b+/Gr1+ cells infiltrating B16-W6 pSIL10
tumours with respect to control. Of notice, the percentage
of MDSCs in B16-F1 tumours at a late stage of growth,
in which A-SMase was spontaneously downregulated [18],
was similar to that of B16-W6 pSIL10 tumours (Supplemen-
tary Figure 1(a) in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/370482). These observations
support the role of A-SMase downregulation in favouring the
recruitment of MDSCs at the tumour lesion.
3.2. A-SMase-Related MDSC Accumulation Determines an
Immunosuppressive Microenvironment. MDSCs exert their
immunosuppressive function through the impairment of
DCs (CD11c+ cells) and cytotoxic T lymphocytes (CD8+ cells)
[25–27] and the recruitment of Tregs (CD4+/CD25+/Foxp3+
cells) [40]. Flow cytometry analysis of immune cells from
explanted melanomas showed a significant decrease of
CD11c+ cells at B16-W6 pSIL10 tumour site when com-
pared to control (Figure 2(a)). Interestingly recruited DCs
displayed an immature and anergic phenotype as indi-
cated by the reduction of the costimulatory markers CD80
and MHCII (Figure 2(b)). Although we did not observe a
difference in CD8+ and CD4+ T infiltrating lymphocytes
(Figures 2(c) and 2(d)), we found a significant increase in
the number of Tregs in B16-W6 pSIL10 tumours with respect
to control (Figure 2(e)). Similar results were obtained in
B16-F1 melanoma at late stage of growth (Supplementary
Figure 1(b)). Taken together, these results indicate that a
low expression of A-SMase in melanoma cells induces an
immunosuppressive tumour microenvironment.
3.3. Restoring A-SMase Expression Switches the Tumour
Microenvironment from a Pro- to an Antitumoural Phenotype
and Reduces Melanoma Growth. To demonstrate unambigu-
ously that A-SMase expression by melanoma cells modu-
lates tumour microenvironment, different gain-of-function
models of A-SMase were generated by stable transfection
of A-SMase in B16-F1 cells. Measurements of A-SMase
mRNA (Figure 3(a)), protein expression (Figure 3(b)), and
activity (Figure 3(c)) in these A-SMase transfected clones
with respect to parental control (B16-pEF1) allowed us to
select B16-B1A as the cells overexpressing A-SMase to be
used for in vivo studies as follows. In particular, mice
were subcutaneously injected with B16-B1A cells and the
explanted melanomas analysed for A-SMase expression and
the immune cell composition.The cell clone B16-pEF1 served
as control. As expected, B16-B1A tumour maintained stable
levels of A-SMase mRNA levels during growth (Figure 4(a)).
Of interest, the number of MDSCs and Tregs decreased sig-
nificantly in B16-B1A tumourwhen compared to control (Fig-
ures 4(b) and 4(c)). This event was paralleled by the increase
of DCs infiltrate (Figure 5(a)). These cells partially recovered
their maturation status as demonstrated by the increase in
expression of the costimulatory markers CD80 and MHCII
(Figure 5(b)). Unexpectedly, even CD8+ and CD4+ T infil-
trating lymphocytes as well as the CD8+/CD44high activated
T lymphocytes were significantly higher in B16-B1A tumours
with respect to B16-pEF1 ones (Figures 5(c)–5(e)); no differ-
ences were observed in the population of CD4+/CD44high T
lymphocytes (Figure 5(f)). These data indicate that A-SMase
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Figure 1: Downregulation of A-SMase increases the accumulation of MDSCs in melanoma. Tumours were resected when they reached the
volume of ca. 500mm3 and treated to extract mRNA or obtain a cell suspension. (a) qPCR analysis of mRNA of IL-1𝛽, IL-6, IL-10, GM-CSF,
TGF-𝛽1, and TNF-𝛼. The histograms are representative of results obtained from at least seven to twelve different animals per experimental
group. (b) Flow cytometry analysis of tumour-infiltrating immune cells. The cell suspensions obtained from different tumours were stained
with anti-CD11b-APC and anti-Gr1-FITC antibodies. A representative dot plot of CD11b+/Gr1+ cells in the CD11b+ population cell is shown
(upper panel).The histograms represent the results obtained from at least ten to fifteen different animals per experimental group (lower panel).
Values are expressed as mean ± SEM. ∗∗∗𝑃 < 0.001 versus B16-pSILscr control.
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Figure 2: A-SMase inducedMDSCaccumulation determines an immunosuppressivemicroenvironment. Flow cytometry analysis of tumour-
infiltrating immune cells. Tumour cell suspensions obtained from resected tumours were stained with the specific fluorescent conjugated
antibodies for CD11c, CD80, MHCII, CD8, CD4, CD25, and Foxp3 antibodies. (a) A representative dot plot of gated CD11c+ cells is
shown (upper panel). The histograms represent the data obtained from ten to fifteen animals per experimental group (lower panel). (b) A
representative dot plot of CD80+/MHCII+ cells in the CD11c+ cell population is shown (upper panel). The histograms represent the data
obtained from ten to fifteen animals per experimental group (lower panel). (c-d) A representative dot plot of CD8+ cells (c) and CD4+ cells
(d) is shown (upper panel).The histograms represent the data obtained from ten to fifteen animals per experimental group (lower panel). (e) A
representative dot plot of CD25+/Foxp3+ in the CD4+ cell population is shown (upper panel).The histograms represent the data obtained from
ten to fifteen animals per experimental group (lower panel). Values in each histogram are expressed as mean ± SEM. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01
versus B16-pSILscr control.
restoration in melanoma cells results in the establishment
of an antitumoural microenvironment through both the
reduction of protumoural immune cells and the recruitment
of antitumoural immune cells at tumour site.
Finally we addressed whether the overexpression of
A-SMase may have therapeutic efficacy. The analysis of
melanoma apoptosis in vitro revealed that the higher levels of
A-SMase in B16-B1A correlate with an increase of apoptotic
cell number when compared to the B16-pEF1 control cells
(Figure 6(a)), thus confirming the fundamental role played by
A-SMase in sensitivity to apoptosis. Of notice, as shown in the
growth analysis in vivo of Figure 6, we observed a significant
delay in the outgrowth of B16-B1A tumours versus control.
These data are in line with our previous results in which the
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Figure 3: Generation of B16-F1 clones stably expressed A-SMase. Evaluation of A-SMase expression/activity in B16-F1-derived clones
overexpressing A-SMase. The B16-pEF1 clone transfected with the empty vector (pEF1) was used as control. (a) qPCR analysis of A-SMase
expression. (b) Western blotting analysis of A-SMase. Image is representative of at least three independent experiments. TBP was used as
loading control. The histograms represent the densitometric values normalized on TBP. (c) A-SMase activity on cell lysates measured as
sphingomyelin hydrolysis at pH 5.5. Values are expressed as fold increases over control ± SEM (𝑛 = 3). ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001
versus B16-pEF1 control.
silencing of A-SMase resulted in an increase in melanoma
growth [18] and confirms the inverse correlation between A-
SMase expression and melanoma progression.
4. Discussion
The role of A-SMase in the response of tumours to
chemotherapy and radiotherapy is a well-established concept
[14]. Indeed, the enzyme contributes significantly to the
cytotoxic effects of several anticancer drugs such as cisplatin,
retinoids, and doxorubicin [28–32]. Moreover it has been
demonstrated that the peritumoural injection of recombinant
A-SMase sensitises mouse subcutaneous melanomas to the
antineoplastic effects of radiotherapy [33]. Recently, A-SMase
downregulation was shown to favour human and mouse
melanoma ability to grow, invade, and metastasise [18]. We
now show that change of A-SMase expression in cancer cells
is sufficient per se to tune in vivo melanoma growth. In
addition, our data indicated that A-SMase levels modulate
immune cells at tumour site, thus suggesting the role of A-
SMase as an immune-regulating factor of melanoma tumour
microenvironment.
It is well known that the interactions between immune
system components recruited into the tumour microen-
vironment are crucial for tumour development and pro-
gression, relying on inflammatory factors and cells that
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contribute to cell transformation, support cancerous cell
survival, resist immunological destruction, and facilitate
invasion and metastasis [6, 34]. In keeping with the notion
that the protumoural microenvironment can be considered
the product of a developing cross talk between cancerous cells
and stromal cells, here we demonstrate a close correlation
between the extent and type of tumour infiltrate andA-SMase
levels. Specifically, low A-SMase in melanoma accounts for
the high expression of factors involved in inflammation
(i.e., IL-1𝛽, IL-6, GM-CSF, and TNF-𝛼), which have been
positively associated with cancer onset and progression
[6, 34]. In contrast with the A-SMase-mediated inhibitory
effect on proinflammatory cytokines we also found that
low A-SMase in melanoma accounts for the high expres-
sion of the anti-inflammatory cytokines IL-10 and TGF-
𝛽1. Of interest, both cytokines are generally accepted as
major immunosuppressive cytokines expressed in tumours
including melanoma, although there is still a debate on their
effective role in antitumour immune response [6, 34–38].Our
data indicate that A-SMase decrease in melanoma accounts
for the establishment of a high immunosuppressive and
protumoural microenvironment. In this respect, tumours
with low A-SMase levels, that is, B16-F1 psil10 and B16-F1
at late stage of development, display an increase of MDSCs
infiltration, already known to be responsible for the establish-
ment of immunosuppression [5, 39]. MDSCs accumulation
in the tumour mass determines the impairment of DCs and
cytotoxic T lymphocytes [25, 27] and the recruitment of
regulatory Tregs [40]. In this line, in low A-SMase expressing
tumours we found low levels of DCs; of interest these
cells also showed an immature and anergic phenotype, a
typical feature of melanoma infiltrating DCs resulting in the
inability to trigger the activation of tumour specificCD8+ and
CD4+ T lymphocytes [41, 42]. Moreover low A-SMase
expressing tumours displayed increased Treg infiltration
which is often associated with poor clinical outcome and
tumour progression in different cancers [43]. This led to the
hypothesis that the naturally occurring A-SMase decrease in
melanoma cells during tumour progression contributes to the
induction of immune tolerance and immunosuppression in
tumour microenvironment and eventually in the acquisition
of the high aggressive behaviour of melanoma in vivo [18].
In support of this hypothesis, the restoration of A-
SMase expression inmelanoma cells not only reduces tumour
growth and immunosuppression, but also accounts for a high
recruitment in the tumour microenvironment of effector
immune cells with an antitumoural function. Indeed, we
observed a poor homing of MDSCs and Tregs in tumours
in which a sustained expression of A-SMase is maintained
during their progression, that is, B16-B1A. As a consequence,
we observed the increased recruitment of CD8+ and CD4+ T
lymphocytes at the tumour lesion and especially the infiltra-
tion ofmatureDCs andCD8+/CD44high memory/activated T
lymphocytes [44–46]. The accumulation of effector immune
cells such as DCs and CD8+ T lymphocytes into primary
tumour lesions is associated with prolonged survival and a
reduced incidence ofmetastases in patients with several types
of solid cancer, including primary cutaneous melanomas
[47, 48]. Based on this evidence, the current preclinical
and clinical studies regarding melanoma immunotherapy
are centred on the administration of DCs or CD8+ cells
in the form of DC vaccines or adoptive T cell transfer,
preceded by radiotherapy or chemotherapy to induce lym-
phodepletion and the ensuing elimination of immunosup-
pressive MDSCs and Tregs [49–52]. Consistent with these
reports, our findings on the role of A-SMase upregulation
in reprogramming the status of tumour microenvironment
open new vistas in therapeutic perspective. In particular, the
possibility that A-SMase overexpression “educates” tumour
microenvironment against cancer cells encourages the use of
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therapeutic approaches to increase the enzyme expression/
activity. This would create an antitumoural microenviron-
ment suitable either for triggering an appropriate adaptive
immune response against melanoma or for improving the
efficacy of other immunotherapy strategies. In this respect,
restoring A-SMase in melanomas by genetic overexpression
or by recombinant protein administration, a protocol cur-
rently under examination for Niemann-Pick type B patients
[53], might be considered a useful adjuvant for cancer
therapy.
5. Conclusion
The evaluation of the role of A-SMase in many pathophysi-
ological processes is a developing field [14, 28, 54–61]. This
study demonstrates for the first time the central role of A-
SMase expressed by melanoma cells in orchestrating the
cross talk with the surrounding microenvironment. These
interactions are crucial for tumour fate, lying on its rejection
or progression. The discovery of this A-SMase function
exerted on the tumour-infiltrating immune cells suggests that
the antineoplastic effect of the enzyme goes beyond the well-
established role in cancer cell death but involves a more
complex network that may be taken into consideration in the
setting of therapeutic strategies.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This work was supported by “Ministero della Salute, Gio-
vani Ricercatori 2011-2012” grant to Clara De Palma and
“Ricerca Corrente 2015” grant to Emilio Clementi, “Ministero
dell’Istruzione, Universita` e Ricerca, PRIN2010-2011” grants
to EmilioClementi andDavideCervia, “Universita` diMilano,
Giovani Ricercatori-Linea B” grant to Cristiana Perrotta, and
“Associazione Italiana Ricerca sul Cancro (AIRC) IG11365”
grant to Emilio Clementi.
References
[1] D. Grossman and D. C. Altieri, “Drug resistance in melanoma:
mechanisms, apoptosis, and new potential therapeutic targets,”
Cancer and Metastasis Reviews, vol. 20, no. 1-2, pp. 3–11, 2001.
[2] A. H. Enk, J. C. Becker, and G. Schuler, “Immunotherapy
of malignant melanoma—basic principles and novel thera-
peutic approaches,” Journal der Deutschen Dermatologischen
Gesellschaft, vol. 4, no. 8, pp. 635–645, 2006.
[3] R. Wu, M.-A. Forget, J. Chacon et al., “Adoptive T-cell therapy
using autologous tumor-infiltrating lymphocytes for metastatic
melanoma: current status and future outlook,” The Cancer
Journal, vol. 18, no. 2, pp. 160–175, 2012.
[4] V. Umansky, A. Sevko, C. Gebhardt, and J. Utikal, “Myeloid-
derived suppressor cells in malignant melanoma,” Journal der
Deutschen Dermatologischen Gesellschaft, vol. 12, no. 11, pp.
1021–1027, 2014.
[5] C. Meyera, A. Sevko, M. Ramacher et al., “Chronic inflam-
mation promotes myeloid-derived suppressor cell activation
blocking antitumor immunity in transgenic mouse melanoma
model,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 108, no. 41, pp. 17111–17116, 2011.
[6] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity,
inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899,
2010.
[7] A. A. Navarini-Meury and C. Conrad, “Melanoma and innate
immunity—active inflammation or just erroneous attraction?:
melanoma as the source of leukocyte-attracting chemokines,”
Seminars in Cancer Biology, vol. 19, no. 2, pp. 84–91, 2009.
[8] K. N. Kodumudi, A.Weber, A. A. Sarnaik, and S. Pilon-Thomas,
“Blockade of myeloid-derived suppressor cells after induction
of lymphopenia improves adoptive T cell therapy in a murine
model of melanoma,” Journal of Immunology, vol. 189, no. 11, pp.
5147–5154, 2012.
[9] R. Wesolowski, J. Markowitz, and W. E. Carson III, “Myeloid
derived suppressor cells—a new therapeutic target in the
treatment of cancer,” Journal for ImmunoTherapy of Cancer, vol.
1, article 10, 2013.
[10] B. Ogretmen and Y. A. Hannun, “Biologically active sphin-
golipids in cancer pathogenesis and treatment,” Nature Reviews
Cancer, vol. 4, no. 8, pp. 604–616, 2004.
[11] C. De Palma and C. Perrotta, “Ceramide as a target of
chemotherapy: its role in apoptosis and autophagy,” Clinical
Lipidology, vol. 7, no. 1, pp. 111–119, 2012.
[12] L. Riboni, R. Campanella, R. Bassi et al., “Ceramide levels are
inversely associated with malignant progression of human glial
tumors,” Glia, vol. 39, no. 2, pp. 105–113, 2002.
[13] A. Prinetti, D.Millimaggi, S. D’Ascenzo et al., “Lack of ceramide
generation and altered sphingolipid composition are associated
with drug resistance in human ovarian carcinoma cells,” Bio-
chemical Journal, vol. 395, no. 2, pp. 311–318, 2006.
[14] E. L. Smith and E. H. Schuchman, “The unexpected role of
acid sphingomyelinase in cell death and the pathophysiology of
common diseases,”The FASEB Journal, vol. 22, no. 10, pp. 3419–
3431, 2008.
[15] A. E. M. Mahdy, J. C. Cheng, J. Li et al., “Acid ceramidase
upregulation in prostate cancer cells confers resistance to
radiation: AC inhibition, a potential radiosensitizer,”Molecular
Therapy, vol. 17, no. 3, pp. 430–438, 2009.
[16] V. Edmond, F. Dufour, G. Poiroux et al., “Downregulation of
ceramide synthase-6 during epithelial-to-mesenchymal transi-
tion reduces plasmamembrane fluidity and cancer cellmotility,”
Oncogene, vol. 34, no. 19, pp. 996–1005, 2014.
[17] N. H. T. Petersen, O. D. Olsen, L. Groth-Pedersen et
al., “Transformation-associated changes in sphingolipid
metabolism sensitize cells to lysosomal cell death induced by
inhibitors of acid sphingomyelinase,” Cancer Cell, vol. 24, no. 3,
pp. 379–393, 2013.
[18] L. Bizzozero, D. Cazzato, D. Cervia et al., “Acid sphin-
gomyelinase determines melanoma progression and metastatic
behaviour via the microphtalmia-associated transcription fac-
tor signalling pathway,” Cell Death and Differentiation, vol. 21,
no. 4, pp. 507–520, 2013.
[19] C. Perrotta, L. Bizzozero, S. Falcone et al., “Nitric oxide boosts
chemoimmunotherapy via inhibition of acid sphingomyelinase
in a mouse model of melanoma,” Cancer Research, vol. 67, no.
16, pp. 7559–7564, 2007.
[20] C. Perrotta, M. Buldorini, E. Assi et al., “The thyroid hor-
mone triiodothyronine controls macrophage maturation and
12 Mediators of Inflammation
functions: protective role during inflammation,” The American
Journal of Pathology, vol. 184, no. 1, pp. 230–247, 2014.
[21] C. de Palma, F. Morisi, S. Pambianco et al., “Deficient nitric
oxide signalling impairs skeletal muscle growth and perfor-
mance: involvement of mitochondrial dysregulation,” Skeletal
Muscle, vol. 4, article 22, 2014.
[22] D. Cazzato, E. Assi, C. Moscheni et al., “Nitric oxide drives
embryonic myogenesis in chicken through the upregulation of
myogenic differentiation factors,” Experimental Cell Research,
vol. 320, no. 2, pp. 269–280, 2014.
[23] C. Sciorati, T. Touvier, R. Buono et al., “Necdin is expressed in
cachectic skeletal muscle to protect fibers from tumor-induced
wasting,” Journal of Cell Science, vol. 122, part 8, pp. 1119–1125,
2009.
[24] M. Opreanu, M. Tikhonenko, S. Bozack et al., “The uncon-
ventional role of acid sphingomyelinase in regulation of retinal
microangiopathy in diabetic human and animal models,” Dia-
betes, vol. 60, no. 9, pp. 2370–2378, 2011.
[25] G. Schiavoni, L. Gabriele, and F. Mattei, “The tumor microen-
vironment: a pitch for multiple players,” Frontiers in Oncology,
vol. 3, article 90, 2013.
[26] P. C. Rodriguez, D. G. Quiceno, and A. C. Ochoa, “L-
arginine availability regulates T-lymphocyte cell-cycle progres-
sion,” Blood, vol. 109, no. 4, pp. 1568–1573, 2007.
[27] S. Ostrand-Rosenberg, P. Sinha, D. W. Beury, and V. K.
Clements, “Cross-talk between myeloid-derived suppressor
cells (MDSC), macrophages, and dendritic cells enhances
tumor-induced immune suppression,” Seminars in Cancer Biol-
ogy, vol. 22, no. 4, pp. 275–281, 2012.
[28] E. Gulbins and R. Kolesnick, “Raft ceramide in molecular
medicine,” Oncogene, vol. 22, no. 45, pp. 7070–7077, 2003.
[29] S. Lacour, A. Hammann, S. Grazide et al., “Cisplatin-induced
CD95 redistribution into membrane lipid rafts of HT29 human
colon cancer cells,” Cancer Research, vol. 64, no. 10, pp. 3593–
3598, 2004.
[30] S. Brunelli, C. Sciorati, G. D’Antona et al., “Nitric oxide release
combinedwith nonsteroidal antiinflammatory activity prevents
muscular dystrophy pathology and enhances stem cell therapy,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 104, no. 1, pp. 264–269, 2007.
[31] Y. H. Zeidan and Y. A. Hannun, “Activation of acid sphin-
gomyelinase by protein kinase Cdelta-mediated phosphoryla-
tion,” The Journal of Biological Chemistry, vol. 282, no. 15, pp.
11549–11561, 2007.
[32] M. Garcia-Barros, D. Lacorazza, H. Petrie et al., “Host acid
sphingomyelinase regulates microvascular function not tumor
immunity,” Cancer Research, vol. 64, no. 22, pp. 8285–8291,
2004.
[33] E. L. Smith and E.H. Schuchman, “Acid sphingomyelinase over-
expression enhances the antineoplastic effects of irradiation in
vitro and in vivo,” Molecular Therapy, vol. 16, no. 9, pp. 1565–
1571, 2008.
[34] J. Kanterman, M. Sade-Feldman, and M. Baniyash, “New
insights into chronic inflammation-induced immunosuppres-
sion,” Seminars in Cancer Biology, vol. 22, no. 4, pp. 307–318,
2012.
[35] S.-K. Leivonen andV.-M. Ka¨ha¨ri, “Transforming growth factor-
𝛽 signaling in cancer invasion and metastasis,” International
Journal of Cancer, vol. 121, no. 10, pp. 2119–2124, 2007.
[36] J. Kim, R. L. Modlin, R. L. Moy et al., “IL-10 production in
cutaneous basal and squamous cell carcinomas: a mechanism
for evading the local T cell immune response,” Journal of
Immunology, vol. 155, no. 4, pp. 2240–2247, 1995.
[37] S. Mocellin, F. M. Marincola, and H. A. Young, “Interleukin-
10 and the immune response against cancer: a counterpoint,”
Journal of Leukocyte Biology, vol. 78, no. 5, pp. 1043–1051, 2005.
[38] S. Tikoo and N. K. Haass, “Friends or foes: IL-10 and TGF-
beta in melanoma,” Experimental Dermatology, vol. 24, no. 4,
pp. 254–255, 2015.
[39] V. Umansky and A. Sevko, “Melanoma-induced immunosup-
pression and its neutralization,” Seminars in Cancer Biology, vol.
22, no. 4, pp. 319–326, 2012.
[40] E. Schlecker, A. Stojanovic, C. Eisen et al., “Tumor-infiltrating
monocytic myeloid-derived suppressor cells mediate CCR5-
dependent recruitment of regulatory T cells favoring tumor
growth,” Journal of Immunology, vol. 189, no. 12, pp. 5602–5611,
2012.
[41] P. Stoitzner, L. K. Green, J. Y. Jung et al., “Inefficient presentation
of tumor-derived antigen by tumor-infiltrating dendritic cells,”
Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1665–
1673, 2008.
[42] H. Ataera, E. Hyde, K. M. Price, P. Stoitzner, and F. Ronchese,
“Murine melanoma-infiltrating dendritic cells are defective
in antigen presenting function regardless of the presence of
CD4+CD25+ regulatory T cells,”PLoSONE, vol. 6, no. 3, Article
ID e17515, 2011.
[43] W. Zou, “Regulatory T cells, tumour immunity and
immunotherapy,” Nature Reviews Immunology, vol. 6, no.
4, pp. 295–307, 2006.
[44] M. J. Dobrzanski, J. B. Reome, and R. W. Dutton, “Type 1
and type 2 CD8+ effector T cell subpopulations promote long-
term tumor immunity and protection to progressively growing
tumor,” Journal of Immunology, vol. 164, no. 2, pp. 916–925,
2000.
[45] B. J. G. Baaten, C.-R. Li, and L. M. Bradley, “Multifaceted
regulation of T cells by CD44,” Communicative and Integrative
Biology, vol. 3, no. 6, pp. 508–512, 2010.
[46] R. W. Dutton, L. M. Bradley, and S. L. Swain, “T cell memory,”
Annual Review of Immunology, vol. 16, pp. 201–223, 1998.
[47] Y. Ma, G. V. Shurin, Z. Peiyuan, and M. R. Shurin, “Dendritic
cells in the cancer microenvironment,” Journal of Cancer, vol. 4,
no. 1, pp. 36–44, 2013.
[48] O. Preynat-Seauve, P. Schuler, E. Contassot, F. Beermann, B.
Huard, and L. E. French, “Tumor-infiltrating dendritic cells
are potent antigen-presenting cells able to activate T cells and
mediate tumor rejection,” Journal of Immunology, vol. 176, no. 1,
pp. 61–67, 2006.
[49] F. Benencia, L. Sprague, J. McGinty, M. Pate, and M. Muc-
cioli, “Dendritic cells the tumor microenvironment and the
challenges for an effective antitumor vaccination,” Journal of
Biomedicine and Biotechnology, vol. 2012, Article ID 425476, 15
pages, 2012.
[50] C. P. Duong, C. S. Yong, M. H. Kershaw, C. Y. Slaney, and P. K.
Darcy, “Cancer immunotherapy utilizing gene-modifiedT cells:
from the bench to the clinic,”Molecular Immunology, 2015.
[51] O. Itzhaki, D. Levy, D. Zikich et al., “Adoptive T-cell transfer in
melanoma,” Immunotherapy, vol. 5, no. 1, pp. 79–90, 2013.
[52] G. Q. Phan and S. A. Rosenberg, “Adoptive cell transfer for
patients with metastatic melanoma: the potential and promise
of cancer immunotherapy,” Cancer Control, vol. 20, no. 4, pp.
289–297, 2013.
Mediators of Inflammation 13
[53] J. M. Murray, A. M. Thompson, A. Vitsky et al., “Nonclinical
safety assessment of recombinant human acid sphingomyeli-
nase (rhASM) for the treatment of acid sphingomyelinase
deficiency: the utility of animal models of disease in the
toxicological evaluation of potential therapeutics,” Molecular
Genetics and Metabolism, vol. 114, no. 2, pp. 217–225, 2015.
[54] C. Perrotta and E. Clementi, “Biological roles of acid and
neutral sphingomyelinases and their regulation by nitric oxide,”
Physiology, vol. 25, no. 2, pp. 64–71, 2010.
[55] D. Cervia, C. Perrotta, C. Moscheni, C. de Palma, and E.
Clementi, “Nitric oxide and sphingolipids control apoptosis and
autophagy with a significant impact on Alzheimer’s disease,”
Journal of Biological Regulators and Homeostatic Agents, vol. 27,
no. 2, supplement, pp. 11–22, 2013.
[56] E. Assi, D. Cazzato, C. De Palma, C. Perrotta, E. Clementi,
and D. Cervia, “Sphingolipids and brain resident macrophages
in neuroinflammation: an emerging aspect of nervous system
pathology,” Clinical and Developmental Immunology, vol. 2013,
Article ID 309302, 8 pages, 2013.
[57] C. Perrotta, L. Bizzozero, D. Cazzato et al., “Syntaxin 4 is
required for acid sphingomyelinase activity and apoptotic
function,” Journal of Biological Chemistry, vol. 285, no. 51, pp.
40240–40251, 2010.
[58] Y. Li, S. Li, X. Qin et al., “The pleiotropic roles of sphingolipid
signaling in autophagy,” Cell Death and Disease, vol. 5, no. 5,
Article ID e1245, 2014.
[59] F. C. Luft, “Acid sphingomyelinase, autophagy, and atheroscle-
rosis,” Journal of Molecular Medicine, vol. 92, no. 5, pp. 429–431,
2014.
[60] C. Garcia-Ruiz, J. M. Mato, D. Vance, N. Kaplowitz, and J. C.
Ferna´ndez-Checa, “Acid sphingomyelinase-ceramide system in
steatohepatitis: a novel target regulating multiple pathways,”
Journal of Hepatology, vol. 62, no. 1, pp. 219–233, 2015.
[61] C. Perrotta, D. Cervia, C. de Palma et al., “The emerging role of
Acid Sphingomyelinase in autophagy,” Apoptosis, vol. 20, no. 5,
pp. 635–644, 2015.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
